BioSpace News Archive

Arvinas, Inc. announced that management will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10 at 7:00 p.m. ET /4:00 p.m. PT in Las Vegas.

Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will immediately defer current commercialization activities for tebipenem HBr based on feedback from a recent Late Cycle Meeting (LCM) with the U.S. Food and Drug Administration (FDA) regarding Spero’s New Drug Application (NDA) for tebipenem HBr.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO, and Walter Smith, Scientific and Business Development Consultant, of Aclaris will participate in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium.

Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company will release its first quarter 2022 financial results on Thursday, May 12, 2022, before the markets open.

Apellis Pharmaceuticals, Inc. announced today that renowned hematologist Peter Hillmen, MB ChB, PhD, will join the company as head of hematology engagement, effective May 23, 2022.

rBIO, an early-stage synthetic biology company focused on reducing the cost of increasingly costly biologic therapies, announced refinement of its bacteria-based production of insulin.

Rhythm Pharmaceuticals, Inc. today reported financial results and provided a business update for the first quarter ended March 31, 2022.

Stryker (NYSE: SYK) announced today the publication of results from a multicenter, single-blinded, randomized controlled trial comparing Stryker’s InSpace implant with partial repair for the treatment of full-thickness massive irreparable rotator cuff tears (MIRCTs) in the Journal of Bone and Joint Surgery (JBJS).

Orthofix Medical Inc today announced the renewal and expansion of its partnership agreement with MTF Biologics – a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science.

Incyte (Nasdaq:INCY) today reports 2022 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.